Lux Susanne, Milsom Michael D
Division of Experimental Hematology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.
Hemasphere. 2023 Oct 4;7(10):e959. doi: 10.1097/HS9.0000000000000959. eCollection 2023 Oct.
), encoded at the locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context-dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy-resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high-risk patients with "EVI1" hematopoietic malignancies.
EVI1定位于 位点,是一种致癌锌指转录因子,在正常细胞和恶性细胞中发挥多种作用,在造血领域的研究最为广泛。EVI1以依赖于环境的方式与其他转录因子相互作用,调节转录和染色质重塑,从而影响细胞的增殖、分化和存活。有趣的是,它既可以作为转录激活因子,也可以作为转录抑制因子。EVI1在包括神经系统和造血系统在内的不同组织发育过程中表达并发挥重要功能,呈现出严格的时空表达模式。然而,EVI1在多种癌症实体中经常过度表达,包括卵巢癌和胰腺癌等上皮性癌症,以及髓系白血病等血液系统恶性肿瘤。重要的是,EVI1的过度表达通常与非常差的临床结果和治疗抗性相关。因此,EVI1是一个研究改善高危“EVI1”造血系统恶性肿瘤患者预后和治疗的有趣候选对象。